Friday, February 28, 2025 11:37:29 AM
FWIW, I did add a few shares today below $4. For everyone that wants to blame the shorts, why do you now blame the company?
This was a very successful short attack, conditions were perfect for such an action. Negative sentiment in the sector, Iovance mostly met their guidance but didn't beat investor's expectations, 2025 guidance wasn't raised (yet), perception/belief that the company is not growing fast enough, money raised through dilution (somewhat expected and predicted, but still not a positive for most investors), but the short attack was happening before the market went into after hours trading and the full report was known.
I'm going to say this was fully preplanned and orchestrated. Not happy, but such is life in the stock market. Shorts may have seen a chance to start covering especially if they've arrived at the belief that Iovance is going to succeed. If that's the case, they needed to act aggressively and in unison to shake loose a lot of shares.
Good luck to the longs. I believe Iovance still has a very bright future, cancer patients will benefit as a result as will we as investors.
This was a very successful short attack, conditions were perfect for such an action. Negative sentiment in the sector, Iovance mostly met their guidance but didn't beat investor's expectations, 2025 guidance wasn't raised (yet), perception/belief that the company is not growing fast enough, money raised through dilution (somewhat expected and predicted, but still not a positive for most investors), but the short attack was happening before the market went into after hours trading and the full report was known.
I'm going to say this was fully preplanned and orchestrated. Not happy, but such is life in the stock market. Shorts may have seen a chance to start covering especially if they've arrived at the belief that Iovance is going to succeed. If that's the case, they needed to act aggressively and in unison to shake loose a lot of shares.
Good luck to the longs. I believe Iovance still has a very bright future, cancer patients will benefit as a result as will we as investors.
Recent IOVA News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/17/2026 09:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 09:01:25 PM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (Canada) • 04/01/2026 12:49:00 AM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (US) • 04/01/2026 12:49:00 AM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (Canada) • 03/24/2026 02:00:00 PM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (US) • 03/24/2026 02:00:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:12 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:01:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:01:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:00:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 10:00:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2026 10:00:18 PM
- Iovance Biotherapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 02/26/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/24/2026 02:35:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/24/2026 01:00:40 PM
- Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas • GlobeNewswire Inc. • 02/24/2026 12:00:00 PM
